|Evotec AG -- USA Stock|| |
USD 17.46 0.00 0.00%
Member of the Supervisory Board
Ms. Mary C. Tanner was Member of the Supervisory Board of Evotec AG since January 19 2005. She has devoted 22 years to the health care and consumer products industry as Senior Managing Director at Bear Stearns and Lehman Brothers both global investment banks. In 2004 Ms. Tanner founded Life Sciences Partners which specializes in healthcare investment and advisory work following her retirement from Bear Stearns in the same year. During her 22 years at Bear Stearns and Lehman Ms. Tanner led or supervised over 575 transactions including 220 mergers acquisitions and divestitures. Ms. Tanner also developed a specialization in the biotechnology industry as it emerged over the last 20 years. She was NonExecutive Member of the Board of Directors at Synvista Therapeutics Inc. Montvale. Ms. Tanner received her university degree from Harvard in 1973 in philosophy and related fields.
Executive Since 2005
49 4056 0810 http://www.evotec.com
The company has return on total asset (ROA)
of 4.56 %
which means that it generated profit of $4.56 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 11.13 %
meaning that it generated $11.13 on every $100 dollars invested by stockholders.
The company has accumulated 201.63 M in total debt with debt to equity ratio (D/E) of 53.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.68 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
Evotec AG offer drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Hamburg, and employs 1,000 people.